A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients

Blood

Volumn 94, Issue 7, 1999, Pages 2192-2199

  Martin, Paul J ^a,b   Rowley, Scott D ^a   Anasetti, Claudio ^a   Chauncey, Thomas R ^a   Gooley, Ted ^a   Petersdorf, Effie W ^a   Van Burik, Jo Anne ^a   Flowers, Mary E D ^a   Storb, Rainer ^a   Appelbaum, Frederick R ^a   Hansen, John A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; METHOTREXATE;

ADULT; ALLELISM; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HELPER CELL; HLA MATCHING; HLA TYPING; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION;

EID: 0033214650     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2192.419a38_2192_2199     Document Type: Article

References (34)

1. Anasetti C, Hansen J: Bone marrow transplantation from HLA-partially matched related donors and unrelated volunteer donors, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge, MA, Blackwell Scientific, 1993, p 665
2. Hansen JA, Petersdorf E, Martin PJ, Anasetti C: Hematopoietic stem cell transplants from unrelated donors. Immunological Rev 157:141, 1997
3. Martin PJ, Kernan NA: T cell depletion for the prevention of graft-versus-host disease in man, in Burakoff S, Deeg MJ, Ferrara J, Atkinson K (eds): Graft Versus Host Disease: Research and Clinical Management. New York, NY, Marcel Dekker, 1996, p 615
4. Martin PJ: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 178:703, 1993
5. Martin PJ: Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: Potential role of a veto mechanism. Blood 88:962, 1996
6. Martin PJ, Akatsuka Y, Hahne M, Sale G: Involvement of donor T cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 92:2177, 1998
7. Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J: Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:418, 1990
8. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 86:1606, 1995
9. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, Smith AG, Martin PJ, Hansen JA: Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 93:15358, 1996
10. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, Woolfrey AE, Hansen JA: Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92:3515, 1998
11. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
12. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole for fungal infections after marrow transplant - A prospective, randomized, double-blind study. J Infect Dis 171:1545, 1995
13. Wade JC, Newton B, Flournoy N, Myers JD: Oral acyclovir for the prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100:823, 1984
14. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598, 1995
15. Goodrich JM, Boeckh M, Bowden R: Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287, 1994
16. Hansen JA, Martin PJ, Beatty PG, Clark EA, Ledbetter JA: Human T lymphocyte cell surface molecules defined by the workshop monoclonal antibodies ("T cell protocol"), in Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF (eds): Leucocyte Typing: Human Leucocyte Markers Detected by Monoclonal Antibodies. New York, NY, Springer-Verlag, 1984, p 195
17. Martin PJ, Ledbetter JA, Clark EA, Beatty PG, Hansen JA: Epitope mapping of the human surface suppressor/cytotoxic T cell molecule Tp32. J Immunol 132:759, 1984
18. Gooley TA, Martin PJ, Fisher LD, Pettinger M: Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control Clin Trials 15:450, 1994
19. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J, Thomas ED: Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825, 1995
20. Bryant E, Martin PJ: Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation, in Thomas ED, Blume KG, Forman SJ (eds): Hematopoietic Cell Transplantation. Malden, MA, Blackwell Science, 1998, p 197
21. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG, Martin PJ, Hansen JA: Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89:1818, 1997
22. Golding H, Mizuochi T, McCarthy SA, Cleveland CA, Singer A: Relationship among function, phenotype, and specificity in primary allospecific T cell populations: Identification of phenotypically identical but functionally distinct primary T cell subsets that differ in their recognition of MHC class I and class II allodeterminants. J Immunol 138:10, 1987
23. Golding H, Singer A: Specificity, phenotype, and precursor frequency of primary cytolytic T lymphocytes specific for class II major histocompatibility antigens. J Immunol 135:1610, 1985
24. Aparicio P, Jaraquemada D, Lopez de Castro JA: Alloreactive cytolytic T cell clones with dual recognition of HLA-B27 and HLA-DR2 antigens. Selective involvement of CD8 in the class I-directed cytoxicity. J Exp Med 165:428, 1987
25. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962, 1998
26. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myeloid leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993
27. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671, 1998
28. Gallardo D, Garcia-Lopez J, Sureda A, Canals C, Ferra C, Cancelas JA, Berlanga JJ, Brunet S, Boque C, Picon M, Torrico C, Amill B, Martino, Martinez C, Martin-Henao G, Domingo-Albos A, Granena A: Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Bone Marrow Transplant 20:945, 1997
29. Mackall CL, Hakim FT, Gress RE: Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 9:339, 1997
30. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, Polyak T, O'Reilly RJ: Immune reconstitution following T-cell depleted bone marrow transplantation: Effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant 3:65, 1997
31. Wald A, Leisenring W, van Burik J-A, Bowden RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459, 1997
32. Pirsch JD, Maki DG: Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections. Ann Intern Med 104:619, 1986
33. Romani L, Howard DH: Mechanisms of resistance to fungal infections. Curr Opin Immunol 7:517, 1995
34. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA: Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 324:654, 1991